V

Velocity Clinical Research | Baton Rouge, LA

Research site

(Unclaimed)

Location

7912 Summa Avenue, Baton Rouge, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Bupropion Hydrochloride

ESK-001

RGT001-075

Naltrexone Hydrochloride

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccin...

Enrolling

SARS-CoV-2

Biological: mRNA-1273 Variant-containing Formulation

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Enrolling

Obesity

Drug: Placebo

Drug: Naltrexone-Bupropion (NB) Combination

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis (ONWARD3)

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Active, not recruiting

Psoriasis

Severe Psoriasis

Drug: Open-Label ESK-001

Drug: Blinded ESK-001

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss...

Active, not recruiting

Obesity or Overweight

Drug: Placebo Comparator

Drug: RGT001-075